Using Directed Evolution to Develop New Vectors for Genetic Medicines

Alan Cohen, senior vice president of clinical development and therapeutic area head of pulmonology for 4DMT, discusses the limitations of existing vectors for genetic medicines, 4DMT’s directed evolution platform technology, and its programs in cystic fibrosis and Fabry disease.